Ayahuasca and Kambo intoxication after alternative natural therapy for depression, confirmed by mass spectrometry
We present a case report about an acute intoxication episode after an oral administration of Ayahuasca and dermal exposure of Kambo for treatment of depression. The clinical features observed were hallucination, agitation, tremors of extremities, oral paresthesia, skin lesions and seizures. Diazepam was administered by the emergency service and was effective in controlling hallucination, but failed to control agitation and seizures.
Patient biological fluids (urine and serum) and the samples of Ayahuasca and Kambo were submitted to toxicological analysis using liquid-liquid extraction followed by liquid chromatography–tandem mass spectrometry and high-resolution electrospray ionization-mass spectrometry.
The main active compounds present in Ayahuasca, N,N-dimethyltryptamine, harmine, harmaline and tetrahydroharmine were found and quantified in the different samples, confirming the use by the patient. In Kambo secretion used in the ritual, we were able to find sixteen potently active peptides: adenoregulin, bombesin, bombesinnona peptide, bradykinin -phe(8)-psi-CH2NH-arg(9)-, caerulein, deltorphin, neurokinin B, phyllomedusin, phyllocaerulein, phyllokinin, phyllolitorin, preprotachykinin B (50–79), ranatachykinin A, sauvagine, T-kinin and urechistachykinin II.
The patient was discharged the day after exposure without any sequel. Clinical and toxicological analysis indicated that the symptoms presented by the patient occurred due to a joint action produced by the substances identified in both materials. To the best of our knowledge, this is the first case involving probable intoxication by simultaneous administration of Ayahuasca and Kambo.
KeywordsAyahuasca Kambo Depression treatment N,N-Dimethyltryptamine Adenoregulin High-resolution ESI-MS
The authors thank all the institutions, Coordination for Improvement of Personnel with Higher Education—CAPES (Process Number 23038.006844/2014-46), The National Council for Scientific and Technological Development—CNPq (Process Number 830525/1999-8) and São Paulo Research Foundation—FAPESP (Process Number 2015/10650-8 and 2016/23157-0) for the fellowships and the financial support.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
The small amounts of blank human blood (to be prepared to serum) and urine samples were collected from healthy volunteers after obtaining the informed consent. This article does not contain any studies with animals performed by any of the authors.
- 2.WHO – World Health Organization (2017) Depression. http://www.who.int/mediacentre/factsheets/fs369/en/. Accessed 2 Sep 2017
- 4.Yip AG, George MS, Tendler A, Roth Y, Zangen A, Carpenter LL (2017) 61% of unmedicated treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial. Brain Stimul 10:847–849. https://doi.org/10.1016/j.brs.2017.02.013 CrossRefPubMedGoogle Scholar
- 5.Osório FL, Sanches RF, Macedo LR, dos Santos RG, Maia-de-Oliveira JP, Wichert-Ana L, de Araujo DB, Riba J, Crippa JA, Hallak JE (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr 37:13–20. https://doi.org/10.1590/1516-4446-2014-1496 CrossRefGoogle Scholar
- 6.Conelea CA, Philip NS, Yip AG, Barnes JL, Niedzwiecki MJ, Greenberg BD, Tyrka AR, Carpenter LL (2017) Transcranial magnetic stimulation for treatment-resistant depression: naturalistic treatment outcomes for younger versus older patients. J Affect Disord 217:42–47. https://doi.org/10.1016/j.jad.2017.03.063 CrossRefPubMedGoogle Scholar
- 11.Lanaro R, Calemi DB, Togni LR, Costa JL, Yonamine M, de Cazenave SO, Linardi A A (2015) Ritualistic use of ayahuasca versus street use of similar substances seized by the police: a key factor involved in the potential for intoxications and overdose? J Psychoactive Drugs 47:132–139. https://doi.org/10.1080/02791072.2015.1013202 CrossRefPubMedGoogle Scholar
- 14.CONAD Conselho Nacional de Políticas sobre Drogas 2010. Resolution N.1, Jan 25, 2010. http://www.mpgo.mp.br/portal/arquivos/2013/07/30/11_33_03_744_resolucao_n_1__de_25_de_janeiro_de_2012___conad.pdf. Accessed 2 Sep 2017
- 19.Erspamer V, Erspamer GF, Severini C, Potenza RL, Barra D, Mignogna G, Bianchi A (1993) Pharmacological studies of ‘sapo’ from the frog Phyllomedusa bicolor skin: a drug used by the Peruvian Matses Indians in shamanic hunting practices. Toxicon 31:1099–1111. https://doi.org/10.1016/0041-0101(93)90125-3 CrossRefPubMedGoogle Scholar
- 23.Maurer HH, Pfleger K, Weber AA (2007) Mass spectral and GC data of drugs, poisons, pesticides, pollutants and their metabolites, 3rd edn. Wiley-VCH, WeinheimGoogle Scholar
- 24.UNODC (2009) Guidance for the validation of analytical methodology and calibration of equipment used for testing of illicit drugs in seized materials and biological specimens. http://www.unodc.org/documents/scientific/validation_E.pdf. Accessed 9 Dec 2015
- 25.Lee H, Naughton NN, Woods JH, Ko MCH (2003) Characterization of scratching responses in rats following centrally administered morphine or bombesin. Behav Pharmacol 14:501–508. https://doi.org/10.1097/01.fbp.0000095082.80017.0f CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Jayasena CN, Comninos AN, Stefanopoulou E, Buckley A, Narayanaswamy S, Izzi-Engbeaya C, Abbara A, Ratnasabapathy R, Mogford J, Ng N, Sarang Z, Ghatei MA, Bloom SR, Hunter MS, Dhillo WS (2015) Neurokinin B administration induces hot flushes in women. Sci Rep 5:8466. https://doi.org/10.1038/srep08466 CrossRefPubMedPubMedCentralGoogle Scholar